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CAN WE DO BETTER IN MANAGEMENT OF NEUTROPENIC FEVER IN HE-
MATOLOGICAL PATIENTS?
Poire, X., Black, S., Ayala, L., McBride, P., McCall, P., Steinhauer, C.,
Garcia, I., Kline, J.P., Artz, A., Odenike, O., Larson, R.A., Stock, W.,
van Besien, K. The University of Chicago, Chicago, IL
Neutropenic fever (NF) remains a frequent and life-threaten-
ing complication among patients with hematological malignan-
cies. Early observations of rapid deterioration of bacterial
infections in NF patients support the current standard of empir-
ical and prompt administration of antibacterial therapy as soon
as fever developed. Alerted by anecdotal observations of delayed
antibiotic administration in some of our patients, we started in
March 2006 an observational study in 20 randomly collected
NF patients hospitalized in the Bone Marrow Transplantation
Unit. We observed a median time to antibiotics administration
of 3 hours with delays as long as 69 hours. The reasons for de-
lays were mainly due to internal safety policies governing drug
administration. This strict procedure implemented a step by
step process including fever notification by nurses, physician
evaluation, pharmacy delivery and many others steps which gen-
erated underestimated and unexpected delays, and which inter-
fered with rapidity of interventions. Our policy was changed
to include availability of antibiotics on the transplant unit and
immediate administration upon NF. Many other steps were
eliminated from the procedure. We then evaluated 20 patients
in July 2006 and subsequently 10 consecutive patients every 6
months until October 2008. This intervention has been success-
ful and antibiotics are now consistently administered within
60 minutes of fever notification. Severe anaphylactic reactions
or inappropriate use of broadspectrum antibiotics has not been
observed.
Our data show that commonly utilized internal safety policies may
adversely affect the efficacy of treatment interventions and may ulti-
mately impair the safety and efficacy of management of neutropenic
patients.286
COMBINATION OF VORICONAZOLE AND ANIDULAFUNGIN AS PRIMARY
THERAPY IN HEMATOLOGIC PATIENTS
Cetkovsky, P., Kouba, M., Markova, M., Kolar, M., Hricinova, M.,
Mertova, J., Salek, C., Vitek, A., Cermak, J., Soukup, P. Institute of He-
matology and Blood Transfusion, Prague, Czech Republic
Background: Invasive aspergillosis (IA) has been recognized as one
of the leading infection-related cause of death in hematologic pa-
tients (pts). Voriconazole has been approved for primary (first-
line) therapy of IA. However, outcomes remain poor, especially
in hematopoietic stem cell transplant (HSCT) pts. Existing limited
data have documented improved survival rates with the use of com-
bination therapy; the succesfull application of the voriconazole and
echinocandin has also been described. It seems to be rationale to
use combination antifungal therapy at the beginning of fungal com-
plication, because benefits of combination therapy may be underes-
timated if used late in the course of progressive and refractory
fungal infection.
Methods:Authors evaluated the outcomes of eleven pts (7 males and
4 females), aged 45 years (21-59) treated for hematological maligna-
cies (AML, ALL,MDS,HCL,MPS); allogeneic HSCTwas made in
6 pts. Combination therapy consisting of voriconazole and anidula-
fungine was used in 6 pts for probable IA; 5 pts were treated pre-
emptively or empirically.
Results:A favorable response to combination antifungal therapy
was obtained in 7 pts (64%), complete response in 2 and par-
tial in 5 pts; progression was observed in 4 pts (36%). Overall,
the combination therapy was well tolerated, there were no in-
terruptions or reductions of the therapy due to toxicity or side
effects.
Conclusions: Combination of voriconazol and anidulafungin
might be considered preferable first-line therapy for subsets of
hematologic pts.287
SAFETY AND EFFECTIVENESS OF INTRAVENOUS PENTAMIDINE AS A
FIRST LINE PNEUMOCYSTIS JIROVECI PNEUMONIA (PJP) PROPHYLAXIS
IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC
PROGENITOR CELL TRANSPLANT (AHPCT)
Drillon, M.A.1, Chaleff, S.2, Duerst, R.1, Klein-Gitelman, M.3,
Kletzel, M.1 1Northwestern University Feinberg School of Medicine, Chi-
cago, IL; 2Maine Children’s Cancer Program, Scarborough, ME; 3North-
western University Feinberg School of Medicine, Chicago, IL
Pneumocystis jiroveci pneumonia (PJP) is a major cause of mor-
bidity and mortality in immune-compromised patients. Currently,
trimethoprim-sulfamethoxazole (TMP-SMZ) is the preferred first
line agent for PJP prophylaxis but many patients do not tolerate it.
Alternative agents are aerosolized or intravenous pentamidine, dap-
sone, and atovaquone. A retrospective analysis of pediatric patients
undergoing AHPCT who received I.V. pentamidine as PJP prophy-
laxis was undertaken to evaluate I.V pentamidine for its safety and
potential efficacy.
Patients and Methods. The records of 320 pediatric patients
who underwent AHPCT between January 1996 and October
2007 at Children’s Memorial Hospital and received intravenous
pentamidine monthly for PJP prophylaxis were analyzed. Two
hundred twenty-two had malignancies and 98 non-malignant dis-
eases. Pentamidine was administered monthly (4 mg/kg as a 2 hr
infusion) beginning on day –1 and continued through day +180.
Adverse events were categorized as severe if the drug was dis-
continued and mild when the reaction required only premedica-
tion prior to future doses or no changes to administration of
pentamidine.
Results. Patients received an average of 6 doses of IV pentamidine
(range 1-27, median 5). Patients were censored if they succumbed
from complications or relapsed within 6 months of AHPCT. Sixteen
patients experienced 20 adverse effects attributed to intravenous
pentamidine that included localized reaction (n5 2), gastrointestinal
intolerance (n5 6), rash (n5 1), respiratory symptoms (n5 10) and
Systemic (n5 2). Eight patients required discontinuation of IV pent-
amidine due to intolerance after 1-14 doses (median 2). Fifty-four
patients died before day 100, 21 from pulmonary complications. 7
more died of pulmonary complications between day +100
and + 180. None of the 320 patients including those who died from
pulmonary causes developed PCP during the period of prophylaxis
with IV pentamidine.
Conclusion: Intravenous pentamidine appears to be a safe and po-
tentially effective first line prophylactic agent for PJP in pediatric pa-
tients undergoing AHPCT.
Pulmonary Mortalities prior to day 1180Prior to d 1100
Non Infectious Infectious
Pulmonary Failure 6 Instertitial Pneumonia no PJP 1
ARDS 1 Asp[ergillosis 1
Pulmonaqry Hemorrage 4 Pseudomonas pneumonia 1CMV pneumonia 1
parainfluenza ARDS 1
ARDS/Pseudomonas 1
Pneumonia NOS 3d1 100-to 1180
Pulmonary hemorrage 1 Fungal pneumonia 2
ARDS/ Hemorrage 1 Aspiration pneumonia 1288
ADEQUACY OF NUTRITIONAL SUPPORT IN PAEDIATRIC BLOOD AND
MARROW TRANSPLANTATION
Cohen, J.E., Maurice, L. Sydney Children’s Hospital, Randwick, NSW,
Australia
Objectives:The use of nutrition support has become standard prac-
tice during paediatric blood and marrow transplantation (BMT).
Despite the importance of nutrition, inadequate nutrition supple-
mentation does occur during this time, though the specifics of this
have not been previously documented.
Method:We completed a retrospective audit of the nutritional sup-
plementation of 34 paediatric patients admitted for either an
